Aafke H. Honkoop

3.6k total citations
33 papers, 1.5k citations indexed

About

Aafke H. Honkoop is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Aafke H. Honkoop has authored 33 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 13 papers in Cancer Research and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Aafke H. Honkoop's work include Cancer Treatment and Pharmacology (16 papers), Breast Cancer Treatment Studies (11 papers) and HER2/EGFR in Cancer Research (10 papers). Aafke H. Honkoop is often cited by papers focused on Cancer Treatment and Pharmacology (16 papers), Breast Cancer Treatment Studies (11 papers) and HER2/EGFR in Cancer Research (10 papers). Aafke H. Honkoop collaborates with scholars based in Netherlands, United States and Costa Rica. Aafke H. Honkoop's co-authors include Sabine C. Linn, Frans Erdkamp, Gabe S. Sonke, Herbert M. Pinedo, Klaas Hoekman, Robert S. de Jong, Cornelis J.A. Punt, Miriam Koopman, Jelle Wesseling and Erik van Werkhoven and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Aafke H. Honkoop

33 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aafke H. Honkoop Netherlands	17	1.1k	495	364	207	189	33	1.5k
Lola A. Fashoyin‐Aje United States	20	1.1k 0.9×	349 0.7×	450 1.2×	216 1.0×	295 1.6×	69	1.9k
Veronica Lonati Italy	22	1.3k 1.1×	405 0.8×	656 1.8×	307 1.5×	296 1.6×	42	1.8k
Thomas E. Seay United States	15	1.7k 1.5×	558 1.1×	502 1.4×	308 1.5×	258 1.4×	20	2.2k
Luis Chu United States	12	797 0.7×	412 0.8×	539 1.5×	309 1.5×	399 2.1×	18	1.5k
A. Antón Spain	18	1.3k 1.1×	492 1.0×	695 1.9×	104 0.5×	178 0.9×	103	1.7k
J.-Y. Douillard France	15	1.0k 0.9×	475 1.0×	891 2.4×	252 1.2×	264 1.4×	59	1.8k
Maria Carmela Piccirillo Italy	26	1.2k 1.1×	408 0.8×	787 2.2×	152 0.7×	502 2.7×	94	2.3k
R. Largillier France	14	940 0.8×	527 1.1×	334 0.9×	231 1.1×	162 0.9×	47	1.5k
Jolanda Schrama Netherlands	12	1.8k 1.6×	431 0.9×	667 1.8×	370 1.8×	346 1.8×	16	2.3k
Gun Min Kim South Korea	18	785 0.7×	351 0.7×	549 1.5×	136 0.7×	260 1.4×	91	1.3k

Countries citing papers authored by Aafke H. Honkoop

Since Specialization

Citations

This map shows the geographic impact of Aafke H. Honkoop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aafke H. Honkoop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aafke H. Honkoop more than expected).

Fields of papers citing papers by Aafke H. Honkoop

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aafke H. Honkoop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aafke H. Honkoop. The network helps show where Aafke H. Honkoop may publish in the future.

Co-authorship network of co-authors of Aafke H. Honkoop

This figure shows the co-authorship network connecting the top 25 collaborators of Aafke H. Honkoop. A scholar is included among the top collaborators of Aafke H. Honkoop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aafke H. Honkoop. Aafke H. Honkoop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Geurts, Sandra M. E., Irene E.G. van Hellemond, Astrid C P Swinkels, et al.. (2023). The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer. JNCI Cancer Spectrum. 7(6). 4 indexed citations

Tjan‐Heijnen, Vivianne C. G., Sandra M. E. Geurts, Ingeborg J. H. Vriens, et al.. (2023). Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial. EClinicalMedicine. 58. 101901–101901. 11 indexed citations

Sonke, Gabe S., Vincent van der Noort, Astrid C P Swinkels, et al.. (2023). Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).. Journal of Clinical Oncology. 41(17_suppl). LBA1000–LBA1000. 55 indexed citations

Munck, Linda de, Marie-Jeanne T. F. D. Vrancken Peeters, Mireille J. M. Broeders, et al.. (2021). Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study. Journal of Hematology & Oncology. 14(1). 64–64. 67 indexed citations

Erdkamp, Frans, Marta López‐Yurda, Jeany M. Rademaker-Lakhai, et al.. (2020). Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer. Acta Oncologica. 59(6). 713–722. 3 indexed citations

Derksen, Jeroen W. G., Sophie A. Kurk, Petra H. Peeters, et al.. (2020). The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer. Journal of Cachexia Sarcopenia and Muscle. 11(4). 919–928. 23 indexed citations

Hellemond, Irene E.G. van, Carolien H. Smorenburg, Petronella G.M. Peer, et al.. (2020). Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial. Breast Cancer Research and Treatment. 180(3). 675–685. 4 indexed citations

Ramshorst, Mette S. van, Anna van der Voort, Erik van Werkhoven, et al.. (2018). Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. 19(12). 1630–1640. 245 indexed citations

Bos, Monique E.M.M., Marta López‐Yurda, Jeany M. Rademaker-Lakhai, et al.. (2018). Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG). Breast Cancer Research and Treatment. 172(2). 413–423. 12 indexed citations

10.

Hellemond, Irene E.G. van, Ingeborg J. H. Vriens, Petronella G.M. Peer, et al.. (2017). Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure. JNCI Journal of the National Cancer Institute. 109(12). 22 indexed citations

11.

Tjan‐Heijnen, Vivianne C. G., Ingeborg J. H. Vriens, Petronella G.M. Peer, et al.. (2017). Anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.. Journal of Clinical Oncology. 35(15_suppl). 523–523. 1 indexed citations

12.

Lam, Siu W., Nienke M. Nota, Agnes Jager, et al.. (2016). Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy. Clinical Cancer Research. 22(7). 1611–1620. 17 indexed citations

13.

Drooger, Jan C., Harm van Tinteren, Albert J. ten Tije, et al.. (2016). A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy‐free approach in HER2‐positive metastatic breast cancer: The HAT study (BOOG 2008‐2003), a Dutch Breast Cancer Research Group trial. Cancer. 122(19). 2961–2970. 3 indexed citations

14.

Custers, José A. E., Marieke Gielissen, Johannes H.W. de Wilt, et al.. (2016). Towards an evidence-based model of fear of cancer recurrence for breast cancer survivors. Journal of Cancer Survivorship. 11(1). 41–47. 41 indexed citations

15.

Lam, Siu W., Aafke H. Honkoop, Nienke M. Nota, et al.. (2013). Plasma VEGF-a, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X).. Journal of Clinical Oncology. 31(15_suppl). 1072–1072. 3 indexed citations

16.

Honkoop, Aafke H., Sylvia A. Luykx‐de Bakker, Klaas Hoekman, et al.. (1999). Prolonged Neoadjuvant Chemotherapy with GM-CSF in Locally Advanced Breast Cancer. The Oncologist. 4(2). 106–111. 36 indexed citations

17.

Honkoop, Aafke H., et al.. (1998). Management of Stage III Breast Cancer. Oncology. 55(3). 218–227. 11 indexed citations

18.

Linn, Sabine C., Herbert M. Pinedo, J van Ark-Otte, et al.. (1997). Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. International Journal of Cancer. 71(5). 787–795. 7 indexed citations

19.

Honkoop, Aafke H., Herbert M. Pinedo, Johannes S. de Jong, et al.. (1997). Effects of Chemotherapy on Pathologic and Biologic Characteristics of Locally Advanced Breast Cancer. American Journal of Clinical Pathology. 107(2). 211–218. 99 indexed citations

20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact